Cue Biopharma (CUE)

Cue Biopharma (CUE): My calculated “moonshot.” After its post-IPO crash, the company has right-sized, and is continuing to extend it’s runway through it’s clinical trial progress unlocking new payment milestones and partnerships. The small initial invest caps the downside risk, and if it goes right, the growth could be exponential.